BLA 761134 · Evive Biotechnology
Ryzneuta
Efbemalenograstim Alfa-Vuxw · Injection · Leukocyte Growth Factor
NovelCDER novel approval, Nov 16, 2023: To treat neutropenia
Last checked: Nov 20, 2026Latest source record: Nov 16, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2023
Nov 16, 2023
Approved uses
1
Original approval plus efficacy supplements
Registered trials
6
0 Phase 3, 2 recruiting
FAERS reports
45
45 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Oct 20, 2026.
1. INDICATIONS AND USAGE RYZNEUTA is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia. Limitations of Use RYZNEUTA is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation. RYZNEUTA is a leukocyte growth factor indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia. ( 1 ) Limitations of Use RYZNEUTA is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation. ( 1 )
Mechanism: Efbemalenograstim alfa-vuxw is a colony-stimulating factor that acts on hematopoietic cells by binding to specific cell surface receptors, thereby stimulating proliferation, differentiation, commitment, and end cell functional activation.
Therapeutic areas: Hematology and blood cancers
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- RYZNEUTA · EFBEMALENOGRASTIM ALFA-VUXW 20MG/ML · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Efbemalenograstim Alfa" as an intervention, any sponsor and status, largest first.
Henan Cancer HospitalGovernment (non-federal)
NCT07187908 · 1,076 participants (planned) · Start Jan 1, 2025 · Primary completion Oct 2026
Drug: Efbemalenograstim alfa Injection · For: Primary/Secondary Prevention; High Risk for Febrile Neutropenia of Chemotherapy Regimens; Intermediate Risk of Chemotherapy Regimens Associated With Other Risk Factors in Febrile Neutropenia
Sites: Zhengzhou, China
Shandong Cancer Hospital and InstituteAcademic, hospital or other
NCT06649448 · 200 participants (planned) · Start Oct 10, 2024 · Primary completion Dec 31, 2025
Drug: Efbemalenograstim alfa Injection; carboplatin/cisplatin-etoposide and 3 more · For: Solid Tumor Cancer; Chemotherapy Induced Neutropenia; G-CSF
Sites: Jinan, China
Tianjin Medical University Cancer Institute and HospitalAcademic, hospital or other
NCT06143735 · 99 participants (planned) · Start Dec 31, 2023 · Primary completion Dec 31, 2024
Drug: Efgbemalenograstim alfa · For: Non Small Cell Lung Cancer
Sites: Zhengzhou, China; Wuhan, China; Hohhot, China · 10 sites in all
- Efbemalenograstim Alfa Injection for Ovarian or Cervical Cancer Receiving Chemotherapy RegimenRecruiting
Shandong UniversityAcademic, hospital or other
NCT06251947 · 83 participants (planned) · Start Apr 15, 2024 · Primary completion Jun 2026
Drug: Efbemalenograstim Alfa · For: Ovarian Cancer; Cervical Cancer
Sites: Changsha, China; Nanjing, China; Jinan, China · 6 sites in all
EVIVE BiotechnologyIndustry
NCT02527746 · 18 participants · Start Dec 2012 · Primary completion Dec 2013
Drug: F-627; EC regimen · For: Neutropenia; Breast Cancer
EVIVE BiotechnologyIndustry
NCT02522234 · 15 participants · Start Feb 25, 2014 · Primary completion Aug 19, 2015
Drug: F-627 240 μg/kg; F-627 320 μg/kg · For: Neutropenia
Sites: Shanghai, China
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- anaphylactic shock11
- asthenia8
- dizziness7
- chest discomfort5
- dyspnoea5
- nausea5
- hyperhidrosis4
- pyrexia4
- white blood cell count increased4
- blood pressure decreased3
- myelosuppression3
- neutrophil count decreased3
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2024 | 6 |
| 2025 | 17 |
| 2026 | 22 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Efbemalenograstim Alfa, an Fc Fusion Protein, LongߛActing Granulocyte Colony-Stimulating Factor for Reducing the Risk of Chemotherapy-Induced Neutropenia: Results of a Phase II Randomized, Multicenter, OpenߛLabel Trial.
Ji D, Wang S, Yao W, et al. · Clin Drug Investig 2025 · Randomized Controlled Trial, Multicenter Study
- Efbemalenograstim alfa not inferior to pegfilgrastim in providing neutrophil support in women with breast cancer undergoing myelotoxic chemotherapy: results of a phase 2 randomized, multicenter, open-label trial.
Glaspy J, Bondarenko I, Krasnozhon D, et al. · Support Care Cancer 2024 · Randomized Controlled Trial, Multicenter Study
- A randomized, multicenter phase III Study of once-per-cycle administration of efbemalenograstim alfa (F-627), a novel long-acting rhG-CSF, for prophylaxis of chemotherapy-induced neutropenia in patients with breast cancer.
Zhang Q, Wang Z, Yao W, et al. · BMC Cancer 2024 · Multicenter Study, Randomized Controlled Trial
- Safety and Efficacy of Efbemalenograstim Alfa for Patients at Risk for Chemotherapy-Induced Neutropenia: A Systematic Review and Meta-Analysis.
Das P, Dutta S, Maji S, et al. · Pharmacology 2026 · Systematic Review
- Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Efbemalenograstim Alfa (F-627), a Novel Long-Acting rhG-CSF, in Healthy Chinese Participants: An Open-Label, Single-Center Phase I Study.
Cao Z, Li Y, Hou D, et al. · Clin Drug Investig 2025 · Clinical Trial, Phase I
- Efbemalenograstim alfa, an Fc fusion protein, long-acting granulocyte-colony stimulating factor for reducing the risk of febrile neutropenia following chemotherapy: results of a phase III trial.
Glaspy J, Bondarenko I, Burdaeva O, et al. · Support Care Cancer 2023 · Randomized Controlled Trial, Clinical Trial, Phase III
Sponsor: Evive Biotechnology
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.